Acute Erythroid Leukemia - 171 Studies Found Completed : S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia : Leukemia : 2010-01-29 : Genetic: DNA analysis Genetic: RNA analysi Completed : Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia : Leukemia : 2009-05-09 : Other: flow cytometry Other: immunological Active, not recruiting : Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia : Leukemia : 2009-05-09 : Genetic: gene expression analysis Genetic: Active, not recruiting : Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia : Leukemia : 2009-05-09 : Genetic: microarray analysis Genetic: mole Completed : Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia : Leukemia Myelodysplastic Syndromes : 2009-02-05 : Drug: clofarabine Given IV Terminated : Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia : Leukemia Myelodysplastic Syndrome : 2009-01-07 : Drug: bortezomib 1.3mg/m^2 via Completed : Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy : Leukemia : 2008-08-20 : Drug: azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle Active, not recruiting : Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia : Leukemia : 2008-04-01 : Drug: cytarabine Given IV Terminated : Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer : Graft Versus Host Disease Leukemia Myelodysplastic Syndrom : 2007-11-06 : Biological: alemtuzumab Drug: busulfan Completed : Natural Killer Cells in Older Patients With Acute Myeloid Leukemia : Leukemia : 2007-10-05 : Drug: cytarabine Other: laboratory biomark <<< Previous | Next >>>
